二甲双胍与瑞格列奈配伍治疗2型糖尿病60例分析

目的:探讨二甲双胍与瑞格列奈联合治疗2型糖尿病的临床效果。方法:将120例2型糖尿病患者根据治疗药物应用的不同分为治疗组与对照组,每组各60例,两组均给予瑞格列奈治疗,治疗组加用二甲双胍治疗。结果:两组治疗后FBG、PBG、HbA1c均有明显下降,同时两组治疗后组间比较有显著性差异(P<0.05)。两组治疗后TG及HDL-C较治疗前无明显变化(P>0.05);TC及LDL-C较治疗前降低(P<0.05)。对照组发生低血糖反应4次,占6.7%;治疗组发生低血糖反应3次,占5.0%。两组对比无显著性差异(P>0.05)。结论:二甲双胍与瑞格列奈配伍治疗糖尿病能促进降糖效果的发挥,也有利于控制血脂变化,安全性好,优于单一药物治疗。

知柏地黄汤联合瑞格列奈治疗糖尿病肾病蛋白尿疗效观察

目的:观察知柏地黄汤加味联合瑞格列奈治疗糖尿病肾病蛋白尿的临床效果。方法:将56例糖尿病肾病蛋白尿患者进行研究,随机分为知柏地黄汤联合瑞格列奈治疗的治疗组和单纯瑞格列奈治疗的对照组,每组各28例。结果:治疗组UKN有效率82.14%,优于对照组的60.71%,差异具统计学意义(P<0.05)。两组患者治疗后,治疗组各项指标均低于对照组,差异具有统计学意义(P<0.05,P<0.01)。结论:知柏地黄汤联合瑞格列奈可有效提高糖尿病肾病蛋白尿的临床疗效,具有推广价值。

Study on the interactions of pharmacokinetics and liver distributions between rosuvastatin and repaglinide in rats

In the present study,we aimed to investigate the interactions of pharmacokinetics and liver distributions between rosuvastatin and repaglinide in rats.Coadministration of repaglinide（0.5 mg/kg,1 mg/kg and 2 mg/kg） for 7 d significantly increased the AUC0–24 and Cmax of rosuvastatin（P〈0.01）,but dramatically decreased the CL/F of rosuvastatin（P〈0.01） after a single dose of rosuvastatin（10 mg/kg）.There were no obviously changes in the parameters of Tmax and t1/2.Coadministration of repaglinide also decreased the liver distribution of rosuvastatin（P〈0.01）.Coadministration of rosuvastatin（20 mg/kg） for 7 days significantly increased the AUC0–12 and Cmax of repaglinide（P〈0.05）,and decreased the CL/F of repaglinide（P〈0.01） after a single dose of repaglinide（1 mg/kg）.The liver distribution of repaglinide was also decreased（P〈0.01）.Our animal study indicated that repaglinide could significantly affect the pharmacokinetics and liver distribution of rosuvastatin in rats and vice versa.